NCT04501276 2026-01-08
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients
Adagene Inc
Phase 1 Completed
Clinical Trials
4 trialsNCT04645069 2024-08-14
ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors
Adagene Inc
Phase 1/2 Completed
NCT05277402 2024-02-26
ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Adagene Inc
Phase 1 Completed
NCT02665416 2020-04-07
Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed